



Edaravone administration and its potential association with a new clinical syndrome in cerebral infarction patients: Three case reports

Liu Yang, Xin Xu, Liang Wang, Ke-Bin Zeng, Xue-Feng Wang

Specialty type: Clinical neurology

Provenance and peer review:

Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Peer-review report's scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): D

Grade E (Poor): 0

P-Reviewer: Ait Addi R, Morocco; Arboix A, Spain; Mishra AK, United States

Received: January 21, 2023

Peer-review started: January 21, 2023

First decision: March 10, 2023

Revised: March 24, 2023

Accepted: June 13, 2023

Article in press: June 13, 2023

Published online: July 6, 2023



Liu Yang, Department of Neurology, Central Hospital Affiliated to Chongqing University, Chongqing 400010, China

Xin Xu, Liang Wang, Ke-Bin Zeng, Xue-Feng Wang, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

Corresponding author: Xue-Feng Wang, PhD, Professor, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University, No. 1 Jiankang Road, Yuzhong District, Chongqing 400010, China. wangxfyp@vip.163.com

Abstract

BACKGROUND

Edaravone is a widely used treatment for patients with cerebral infarction and, in most cases, edaravone-induced side effects are mild. However, edaravone-related adverse reactions have been receiving increasing attention.

CASE SUMMARY

We treated three patients with acute cerebral infarction who died following treatment with edaravone. Edaravone is a widely used treatment for patients with cerebral infarction and, in most cases, edaravone-induced side effects are mild. However, edaravone-related adverse reactions have been receiving increasing attention.

CONCLUSION

Our cases highlight the importance of educating clinicians regarding the new edaravone-induced clinical syndromes of cerebral infarction as potentially fatal adverse drug reactions. Considering that no laboratory or confirmatory test exists to diagnose edaravone-induced death from cerebral infarction, clinicians' knowledge is the key element in recognizing this phenomenon.

Key Words: Edaravone; Sudden death; Patients; Cerebral infarction; Case report

©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: We report three patients with acute cerebral infarction who died after edaravone treatment. Edaravone is used to scavenge oxygen free radicals in patients with acute ischemic stroke, and most clinicians are only aware of its damage to kidney function. However, the main symptoms in patients treated with intravenous edaravone, such as rapid disease change, coagulation dysfunction, cardiac arrest and other side effects are rarely reported. The purpose of this paper is to share the experience of edaravone therapy in clinical practice.

Citation: Yang L, Xu X, Wang L, Zeng KB, Wang XF. Edaravone administration and its potential association with a new clinical syndrome in cerebral infarction patients: Three case reports. *World J Clin Cases* 2023; 11(19): 4648-4654

URL: <https://www.wjgnet.com/2307-8960/full/v11/i19/4648.htm>

DOI: <https://dx.doi.org/10.12998/wjcc.v11.i19.4648>

INTRODUCTION

Edaravone is a clinically effective neuroprotective agent and a free radical scavenger that can capture hydroxyl radicals. It was approved for marketing in Japan and China in 2001 and 2005, respectively. Initially indicated for protection against ischemic brain damage, the indications for edaravone have gradually expanded to the treatment of amyotrophic lateral sclerosis[1-5]. However, owing to its widespread clinical application, adverse reactions due to edaravone have also received increasing attention[6-8]. In the earliest randomized controlled trial of edaravone for ischemic stroke treatment, 4 patients in the edaravone and 5 patients in the blank control groups died out of the 125 cases in each group. In the edaravone group, all deaths were caused by cerebral infarction; while in the control group, three patients died of cardiac arrest, pneumonia, and depression suicide, and two patients died of cerebral hernia caused by edema, worsened cerebral infarction, pneumonia, and disseminated intravascular coagulation (DIC) caused by cirrhosis[6]. In 2007, Japanese scholars reported that one patient with cerebral infarction treated with edaravone experienced severe adverse reactions. The patient presented with a sudden disturbance of consciousness and shock 12 d after hospitalization[6]. In 2018, we observed three patients who died of sudden worsening of acute cerebral infarction during treatment with edaravone, which was suspected to be the cause of death.

CASE PRESENTATION

Chief complaints

Case 1: A 63-year-old woman with slurred speech and mental and behavioral abnormalities for ten days was admitted to our hospital.

Case 2: A 65-year-old man was admitted to our hospital due to being unconscious for 11 h.

Case 3: A 71-year-old man was admitted to our hospital due to sudden twisting of the left corner of his mouth for more than five days and difficulty swallowing for two days.

History of present illness

Case 1: A 63-year-old woman with slurred speech and mental and behavioral abnormalities for ten days was admitted to our hospital.

Case 2: A 65-year-old man was admitted to our hospital due to being unconscious for 11 h.

Case 3: A 71-year-old man was admitted to our hospital due to sudden twisting of the left corner of his mouth for more than five days and difficulty swallowing for two days.

History of past illness

Case 1: No significant history of past illness was noted in the patient.

Case 2: The patient had a history of hypertension, diabetes mellitus, and cerebral infarction.

Case 3: The patient had a history of hypertension.

Personal and family history

Personal history and family history were unremarkable.

Physical examination

Case 1: On admission, the patient's vital signs were stable. The patient showed dysarthria, lack of cooperation, level V muscular strength in both limbs, and negative Babinski signs in both limbs.

Case 2: The patient's temperature was 36.6°C, blood pressure was 175/91 mmHg, heart rate was 80 beats/min, and respiratory rate was 16 breaths/min. The patient was in a superficial coma. The left nasolabial fold was slightly shallower than the contralateral side. Upon pain stimulation, the patient responded with an expression of pain and lifted his left limbs from the bed surface, but not the right limbs. Muscle tone of the right limb was lower than that of the left limb. Tendon reflexes on the right side were weaker than those on the left side.

Case 3: On admission, the patient's vital signs were stable. The patient was alert and had symmetrical forehead lines and dysarthria. The right nasolabial fold was slightly shallower than its contralateral part, and the patient's tongue deviated to the right when it was protruded. The patient had normal muscular strength and tone in all four limbs and symmetrical sensation and tendon reflexes. Bilateral Babinski signs were negative.

Laboratory examinations

Case 1: Laboratory examinations, including routine blood tests, liver and kidney function tests, and electrolyte and blood coagulation tests were within normal parameters. Electrocardiography revealed normal sinus rhythm.

Case 2: Examination of blood coagulation status, liver and kidney function, and electrolyte levels after admission revealed no obvious abnormalities. Electrocardiography revealed normal sinus rhythm.

Case 3: Laboratory examinations were within normal parameters. Electrocardiography revealed normal sinus rhythm.

Imaging examinations

Case 1: Head computed tomography (CT) scan showed cerebral infarction in the bilateral parietal lobes with multiple small ischemic lesions (Figure 1A).

Case 2: The patient's emergency head CT scan showed cerebral infarction in the left thalamus and right cerebellar hemisphere (Figure 1B).

Case 3: Head CT scan suggested the probability of lacunar infarction in the left brainstem (Figure 1C).

FINAL DIAGNOSIS

Case 1: Acute cerebral infarction, respiratory failure, and pneumonia.

Case 2: Hypertension, diabetes mellitus, and cerebral infarction.


Case 3: Hypertension, DIC, and cerebral infarction.

TREATMENT

Case 1: The following drugs were prescribed: Aspirin (100 mg once a day)[7,8], atorvastatin (20 mg once a day)[8,9], edaravone (30 mg twice a day), and *Ginkgo biloba* extract[10,11]. On the sixth day after admission, the patient developed dyspnea and showed decreased oxygen saturation. The patient was transferred to the intensive care unit (ICU) for tracheal intubation and mechanical ventilation. Multiple ecchymoses were observed on the patient's body. DIC was diagnosed based on blood coagulation results, and low-molecular weight heparin (0.2 mL twice a day), tranexamic acid (500 mg once a day), fresh frozen plasma (400 mL), and cryoprecipitate (6 U) were administered to the patient. Blood coagulation status improved gradually after treatment. The patient's respiratory condition improved after receiving ceftizoxime, and she was released from the ventilator.

Case 2: The patient received aspirin (100 mg once a day)[7,8], atorvastatin (20 mg once a day)[8,9], edaravone (30 mg twice a day), *Ginkgo biloba* extract[10-13], and ceftizoxime (2 g three times a day) to treat the lung infection. Insulin was pumped intravenously based on increased blood glucose levels.

Case 3: The patient was administered clopidogrel bisulfate (75 mg once a day), atorvastatin (20 mg once a day)[8,9], edaravone (30 mg twice a day), and ozagrel extract.



DOI: 10.12998/wjcc.v11.i19.4648 Copyright ©The Author(s) 2023.

Figure 1 Computed tomography. A: Case 1: Head computed tomography (CT) scan showed cerebral infarction in the bilateral parietal lobes with multiple small ischemic lesions; B: Case 2: The patient's emergency head CT scan showed cerebral infarction in the left thalamus and right cerebellar hemisphere; C: Case 3: Head CT scan suggested the probability of lacunar infarction in the left brainstem.

OUTCOME AND FOLLOW-UP

Case 1: On the tenth day after admission, the patient experienced sudden cardiac and respiratory arrest. After external chest compressions and mechanical ventilation, her heartbeat and breathing were restored. However, two further cardiac arrests occurred, and the patient died after the last attempt at resuscitation failed.

Case 2: On the third day after admission, the patient's consciousness improved into a lethargic state. However, on the fifth day after admission, the patient lapsed into a deep coma and his heart rate gradually decreased. Resuscitation attempts were ultimately unsuccessful.

Case 3: The twisted corner of the mouth rapidly improved. However, sudden cardiac arrest occurred. The heartbeat was restored after external chest compressions, and the patient was alert again. During transfer to the ICU, his heart rate slowed down to 20 beats/min but was restored after external chest compressions. A bedside tracheotomy was performed due to difficulties with orotracheal intubation. Bleeding at the cutting site and urethral bleeding occurred. The coagulation function showed prothrombin time 15.3 s, increased prothrombin time ratio 1.30, increased international normalized ratio 1.31, decreased prothrombin activity 65.2%, activated partial thromboplastin time 32.6 s, thrombin time 18.1 s, and increased D-dimer > 76 mg/L. Fresh frozen plasma (400 mL), cryoprecipitate (6 U), and red blood cell suspension (2 U) were administered to the patient. Compression and carbazochrome sodium sulfonate injection were performed to stop the bleeding, which improved. However, six days after admission, the patient experienced cardiac arrest and died.

DISCUSSION

Edaravone is a newly developed free radical scavenger, and its administration has been used as a clinical therapeutic option for the management of cerebral infarction[6]. In this case, all three patients had acute cerebral infarction. Therefore, we selected edaravone as the therapeutic option for our patients.

The instructions for edaravone clearly suggest that caution should be exercised when using the drug in cardiac patients due to the risk of death[14]. When edaravone was prescribed to elderly patients with cerebral infarction, some experienced a sudden worsening of their condition or died of cardiac arrest[15]. Therefore, we suspected that edaravone may cause serious adverse reactions, although the reason for this remains unknown. Death in patients with cerebral infarction is commonly caused by cerebral hernias in the acute phase of cerebral edema and organ dysfunction resulting from infection accompanied by deterioration of the underlying heart disease[16,17]. This is a noteworthy aspect that should be emphasized, as the acute ischemic stroke etiology in the patients described may also be due to hematological disease[18]. However, in three cases, the patients' condition deteriorated suddenly and they passed away soon after, which is different from the common cause of death we mentioned above. All these cases had the following characteristics: (1) Elderly patients (aged > 60-year-old); (2) patients with acute cerebral infarction but with a small infarct size, no increase in intracranial pressure, and no serious infection; (3) no history of coronary heart disease, no atrial fibrillation or heart failure, and no

abnormal electrocardiography; (4) treatment with edaravone for 4-10 d; (5) rapid deterioration in the patients' condition, including coagulation dysfunction, severe hepatic and renal damage, or sudden cardiac arrest; and (6) poor response to treatment and difficulty in recovering.

Edaravone has also been reported to cause coagulation dysfunctions. In Japan, approximately 400000 patients received edaravone within 4 years of its release in 2001. The registered adverse reactions were 477 cases, including hepatobiliary diseases (0.1%), renal urinary diseases (0.05%), and thrombocytopenia/DIC (0.02%)[5,6]. Both cases 1 and 3 showed coagulation dysfunction, which improved with plasma and cryoprecipitate infusion, and edaravone was discontinued. This suggests that coagulation dysfunction may have occurred before and after cardiac arrest in these aggravated conditions. Therefore, early detection and reasonable treatment of coagulation dysfunction are important. Patients showed tracheal hemorrhage after tracheotomy, massive urethral hemorrhage, and an abnormal coagulation index without a significant decline in platelets, which were in line with the serious adverse reactions of edaravone with a high risk of disseminated or diffuse intravascular coagulation.

Cardiac arrest occurred in all three patients during treatment with edaravone. In cases 2 and 3, cardiac arrest was the only manifestation of early exacerbation. Patients 1 and 3 were successfully resuscitated after short-term cardiac arrest, but all three patients ultimately had a worse prognosis. As none of the three patients had prior heart disease, the cardiac arrest could not be attributed to existing heart disease. Based on our clinical observations, other possible causes of the three deaths could be excluded, including concomitant medications such as aspirin, clopidogrel, atorvastatin, Ginkgo biloba extract, ozagrel extract, and ceftizoxime. There were no severe adverse reactions related to sudden cardiac arrest, and there were no warnings for the medications administered for patients with heart disease according to the instructions for these drugs. Therefore, these drugs are unlikely to cause disease progression or cardiac arrest. During this exacerbation, severe hepatic and renal function impairments were observed in case 3, which have been mentioned as severe adverse reactions caused by the edaravone. Therefore, sudden deterioration of the patients may be due to adverse drug reactions caused by edaravone. However, the cause-and-effect relationship between the three patients' deaths and edaravone's severe adverse reactions still requires confirmation.

In contrast, experimental animal studies have suggested that edaravone treatment improves hepatic injury following ischemia/reperfusion injury, partial hepatectomy, or endotoxin administration[19]. Other researchers have shown that edaravone has beneficial effects on kidney injury induced by ischemia/reperfusion or cisplatin[20-22]. It is possible that edaravone and edaravone-peroxy radicals, which are metabolic products of edaravone, are responsible for these adverse effects; however, the underlying mechanisms remain unclear. Further studies are required to determine the discrepancies between the protective effects observed in previous animal studies and the adverse effects observed in our patients.

CONCLUSION

In summary, these patients exhibited similar clinical characteristics. Although the characteristics of edaravone use that may lead to sudden death have not yet been identified, this series of cases represent a new clinical syndrome. Thus, further studies are needed to characterize the pathophysiology of this syndrome and determine the underlying causes.

FOOTNOTES

Author contributions: Xu X and Wang XF were responsible for the neurological diagnosis and treatment; Yang L, Wang L, and Zeng KB were major contributors to the writing of the manuscript; All authors have read and approved the final version of the manuscript; Yang L and Xu X are co-authors, they equally contributed to the work.

Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.

Conflict-of-interest statement: All the authors have no conflicts of interest to declare.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <https://creativecommons.org/licenses/by-nc/4.0/>

Country/Territory of origin: China

ORCID number: Liu Yang 0000-0003-2742-9168; Xue-Feng Wang 0000-003-2742-4798.

S-Editor: Liu JH

L-Editor: Webster JR

P-Editor: Liu JH

REFERENCES

- 1 **Li LD**, Zhou Y, Shi SF. Edaravone combined with Shuxuening versus edaravone alone in the treatment of acute cerebral infarction: A systematic review and meta-analysis. *Medicine (Baltimore)* 2023; **102**: e32929 [PMID: 36862906 DOI: 10.1097/MD.00000000000032929]
- 2 **Writing Group**; Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. *Lancet Neurol* 2017; **16**: 505-512 [PMID: 28522181 DOI: 10.1016/S1474-4422(17)30115-1]
- 3 **Rosenfeldt F**, Wilson M, Lee G, Kure C, Ou R, Braun L, de Haan J. Oxidative stress in surgery in an ageing population: pathophysiology and therapy. *Exp Gerontol* 2013; **48**: 45-54 [PMID: 22465624 DOI: 10.1016/j.exger.2012.03.010]
- 4 **Cao S**, Wei J, Cai Y, Xiong Z, Li J, Jiang Z, Zhou X, Huang B, Zeng J. Network Pharmacology Prediction and Experimental Verification for Anti-Ferroptosis of Edaravone After Experimental Intracerebral Hemorrhage. *Mol Neurobiol* 2023 [PMID: 36905568 DOI: 10.1007/s12035-023-03279-x]
- 5 **Warner DS**, Sheng H, Batinić-Haberle I. Oxidants, antioxidants and the ischemic brain. *J Exp Biol* 2004; **207**: 3221-3231 [PMID: 15299043 DOI: 10.1242/jeb.01022]
- 6 **Edaravone Acute Infarction Study Group**. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. *Cerebrovasc Dis* 2003; **15**: 222-229 [PMID: 12715790 DOI: 10.1159/000069318]
- 7 **Dengler R**, Diener HC, Schwartz A, Grond M, Schumacher H, Machnig T, Eschenfelder CC, Leonard J, Weissenborn K, Kastrup A, Haberl R; EARLY Investigators. Early treatment with aspirin plus extended-release dipyridamole for transient ischaemic attack or ischaemic stroke within 24 h of symptom onset (EARLY trial): a randomised, open-label, blinded-endpoint trial. *Lancet Neurol* 2010; **9**: 159-166 [PMID: 20060783 DOI: 10.1016/S1474-4422(09)70361-8]
- 8 **Wang G**, Fang B, Yu X, Li Z. [Interpretation of 2018 guidelines for the early management of patients with acute ischemic stroke]. *Zhonghua Wei Zhong Bing Ji Jiu Yi Xue* 2018; **30**: 289-295 [PMID: 29663986 DOI: 10.3760/cma.j.issn.2095-4352.2018.04.001]
- 9 **Blanco M**, Nombela F, Castellanos M, Rodriguez-Yáñez M, García-Gil M, Leira R, Lizasoain I, Serena J, Vivancos J, Moro MA, Dávalos A, Castillo J. Statin treatment withdrawal in ischemic stroke: a controlled randomized study. *Neurology* 2007; **69**: 904-910 [PMID: 17724294 DOI: 10.1212/01.wnl.0000269789.09277.47]
- 10 **Zeng GR**, Zhou SD, Shao YJ, Zhang MH, Dong LM, Lv JW, Zhang HX, Tang YH, Jiang DJ, Liu XM. Effect of Ginkgo biloba extract-761 on motor functions in permanent middle cerebral artery occlusion rats. *Phytomedicine* 2018; **48**: 94-103 [PMID: 30195885 DOI: 10.1016/j.phymed.2018.05.003]
- 11 **Liu Y**, Wu X, Yu Z. Ginkgo leaf extract and dipyridamole injection as adjuvant treatment for acute cerebral infarction: Protocol for systemic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)* 2019; **98**: e14643 [PMID: 30813204 DOI: 10.1097/MD.00000000000014643]
- 12 **Abe M**, Kaizu K, Matsumoto K. A case report of acute renal failure and fulminant hepatitis associated with edaravone administration in a cerebral infarction patient. *Ther Apher Dial* 2007; **11**: 235-240 [PMID: 17498008 DOI: 10.1111/j.1744-9987.2007.00480.x]
- 13 **Lapchak PA**. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? *Expert Opin Pharmacother* 2010; **11**: 1753-1763 [PMID: 20491547 DOI: 10.1517/14656566.2010.493558]
- 14 **Raymond J**, Oskarsson B, Mehta P, Horton K. Clinical characteristics of a large cohort of US participants enrolled in the National Amyotrophic Lateral Sclerosis (ALS) Registry, 2010-2015. *Amyotroph Lateral Scler Frontotemporal Degener* 2019; **20**: 413-420 [PMID: 31131638 DOI: 10.1080/21678421.2019.1612435]
- 15 **Jackson C**, Heiman-Patterson T, Kittrell P, Baranovsky T, McAnanama G, Bower L, Agnese W, Martin M. Radicava (edaravone) for amyotrophic lateral sclerosis: US experience at 1 year after launch. *Amyotroph Lateral Scler Frontotemporal Degener* 2019; **20**: 605-610 [PMID: 31364409 DOI: 10.1080/21678421.2019.1645858]
- 16 **Zhu L**, Huang Z, Sun X, Wu M, Xu Y, Sun Z. The function of mechanical thrombectomy on improving haemodynamics of patients with acute cerebral infarction. *Basic & Clinical Pharmacology & Toxicology* 2019; **124**: 116. Available from: <https://www.zhangqiaokeyan.com/journal-foreign-detail/0704028058275.html>.
- 17 **Chen CJ**, Wang C, Buell TJ, Ding D, Raper DM, Ironside N, Paisan GM, Starke RM, Southerland AM, Liu K, Worrall BB. Endovascular Mechanical Thrombectomy for Acute Middle Cerebral Artery M2 Segment Occlusion: A Systematic Review. *World Neurosurg* 2017; **107**: 684-691 [PMID: 28844911 DOI: 10.1016/j.wneu.2017.08.108]
- 18 **Arboix A**, Jiménez C, Massons J, Parra O, Besses C. Hematological disorders: a commonly unrecognized cause of acute stroke. *Expert Rev Hematol* 2016; **9**: 891-901 [PMID: 27367035 DOI: 10.1080/17474086.2016.1208555]
- 19 **Tsuji K**, Kwon AH, Yoshida H, Qiu Z, Kaibori M, Okumura T, Kamiyama Y. Free radical scavenger (edaravone) prevents endotoxin-induced liver injury after partial hepatectomy in rats. *J Hepatol* 2005; **42**: 94-101 [PMID: 15629513 DOI: 10.1016/j.jhep.2004.09.018]
- 20 **Doi K**, Suzuki Y, Nakao A, Fujita T, Noiri E. Radical scavenger edaravone developed for clinical use ameliorates

- ischemia/reperfusion injury in rat kidney. *Kidney Int* 2004; **65**: 1714-1723 [PMID: 15086910 DOI: 10.1111/j.1523-1755.2004.00567.x]
- 21 **Sato M**, Kashihara N, Fujimoto S, Horike H, Tokura T, Namikoshi T, Sasaki T, Makino H. A novel free radical scavenger, edaravone, protects against cisplatin-induced acute renal damage in vitro and in vivo. *J Pharmacol Exp Ther* 2003; **305**: 1183-1190 [PMID: 12649298 DOI: 10.1124/jpet.102.047522]
- 22 **Koike N**, Sasaki A, Murakami T, Suzuki K. Effect of edaravone against cisplatin-induced chronic renal injury. *Drug Chem Toxicol* 2021; **44**: 437-446 [PMID: 31064223 DOI: 10.1080/01480545.2019.1604740]



Published by **Baishideng Publishing Group Inc**
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Telephone: +1-925-3991568

E-mail: bpgoffice@wjgnet.com

Help Desk: <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

